Eli Lilly Will Use GeneNews' Osteoarthritis Biomarker Technology | GenomeWeb

NEW YORK (GenomeWeb News) – GeneNews said today that under a new agreement drugmaker Eli Lilly will have select access to its osteoarthritis genomic biomarker program.

Toronto-based GeneNews specializes in using functional genomics for biomarker-based early disease diagnosis.

GeneNews Lead Director and Interim CEO Heiner Dreismann said in statement that the firm's Sentinel Principle technology "can be applied to identify biomarkers for virtually any disease or condition and was extensively validated in our osteoarthritis program."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.